Jürgen Bulitta

Jürgen Bulitta Ph.D.

Associate Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (407) 313-7010
Business Email: jbulitta@cop.ufl.edu

About Jürgen Bulitta

Jürgen B. Bulitta, PhD, is an Associate Professor in the Department of Pharmacotherapy and Translational Research at the UF College of Pharmacy. He is supported by the University of Florida’s pre-eminence program in Drug Discovery and Development, and received the Perry E. Foote Eminent Scholar Chair, Endowed Professorship, in 2019. Dr. Bulitta’s research focuses on combating multidrug-resistant bacterial ‘superbugs’ which present one of the three most serious threats to human health.

His mission is to optimize patient therapies and innovative drug development by providing a focal point for translational research in infectious diseases and related areas, and to serve as an internationally-leading, interdisciplinary, collaborative program for translational research.

Dr. Bulitta’s vision is to provide novel solutions and great hope for patients with serious, life-threatening infections by developing new safe and effective therapies. These are informed at the molecular level by an innovative combination of mechanistic, in vitro, animal and quantitative approaches to rationally optimize outcomes in patients. His highly collaborative research program leverages latest pharmacological, microbiological, biochemical and computational approaches. This creates unique translational insights that enable novel therapies and dosing strategies, as well as the design and development of new drugs. We work hard so that we can say “we have an effective therapy for you” when you most need it.

He won 26 peer-reviewed grants (15 as PI) from the NIH, FDA, the Australian equivalents of NIH and NSF, as well as 30 collaborative projects with pharmaceutical industry (total: $35M, 18M active). Dr. Bulitta published 140 peer-reviewed papers and contributed to over 97 phase I-IV clinical trials. He reviewed for several NIH study sections and received 23 awards since 1998. These include the Giorgio Segré Prize 2010 for distinct contributions in the field of pharmacokinetics and pharmacodynamics by the European Federation for Pharmaceutical Sciences (EUFEPS) and the 2012 ASCEPT Denis Wade Johnson & Johnson New Investigators Award. Dr. Bulitta created the Translational Clinical Pharmacology course (PHA6133). He is the creator and developed of the SADAPT-TRAN package that greatly facilitates the development of systems pharmacology models in the S-ADAPT population modeling package.

Honors & Awards

Reviewer for Drug Discovery and Mechanisms of Antimicrobial Resistance [DDR] Study Section
2017 · NIH/NIAID
Teaching and Service Excellence Incentive Award
2017 · UF College of Pharmacy
Career Development Fellow Level II
2014 · Australian National Health and Medical Research Council
ASCEPT Denis Wade Johnson & Johnson New Investigators Award
2012 · The Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)
Giorgio Segré Prize 2010 for distinct contributions in the field of pharmacokinetics and pharmacodynamics
2011 · European Federation for Pharmaceutical Sciences
Discovery Early Career Researcher Award and 3-year Fellowship
2011 · Australian Research Council
Editorial Board Member
2009 · Antimicrobial Agents and Chemotherapy
Best UB fellow research presentation
2008 · SUNY Buffalo
Outstanding Modeling and Simulation Abstract Award
2008 · American Conference on Pharmacometrics
Best UB fellow research presentation
2007 · SUNY Buffalo
Best Fellow Presentation at the post-ICAAC meeting
2007 · International Society of Anti-Infective Pharmacology
Best PhD thesis prize in 2006/07
2007 · The Institute of Chemistry and Pharmacy at the Julius-Maximilians University of Würzburg, Germany
Award for student participation
2006 · 56th Meeting of Nobel Laureates in Lindau, Germany
Fastest studies in chemistry since more than a decade
2003 · Friedrich-Alexander University, Erlangen-Nürnberg, Germany
2002 · German National Academic Foundation
Invited “Young Scientist” speaker at the “90-years anniversary of the Nobel-Prize honoring to Paul Ehrlich”
1998 · The Paul-Ehrlich Society; Frankfurt, Germany
Scholarship (4-yr)
1998 · State of Bavaria, Germany
Best secondary school qualification and best qualification in chemistry
1998 · Primary School and Lyceum, Scheinfeld, Bavaria, Germany
First prize in chemistry (regional competition): “PKPD modeling: Selection of resistant mutants of Staphylococcus epidermidis due to quinolone exposure in sweat“
1998 · “Jugend forscht” (Junior Scientific Competition in Germany)

Research Profile

Dr. Bulitta’s research focuses on multidrug-resistant bacterial ‘superbugs’ which present one of the three most serious threats to human health. His research goals are to develop and rationally optimize novel antibiotic combination dosing strategies and to discover and develop new antibiotics based on mechanistic biological insights which his group generated. Dr. Bulitta’s research focuses on Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. His group is systematically identifying unique penicillin-binding protein (PBP) receptor occupancy patterns using double beta-lactam antibiotic combinations to synergistically kill these ‘superbugs’. Moreover, Dr. Bulitta is developing novel strategies to eradicate non-replicating bacterial persisters via available antibiotics and has pioneered the field of mechanism-based and Quantitative and Systems Pharmacology modeling of antibiotics. Dr. Bulitta’s group leverages latest dynamic in vitro infection models, biochemical and molecular studies, LC-MS/MS bioanalysis, as well as latest pharmacometrics methodology to develop and rationally optimize efficacious antibiotic combinations. His highly collaborative research involves an international network of academic, clinical and industry scientists. Dr. Bulitta is collaborating with experts in animal infection models, antibiotic drug development, bacterial resistance mechanisms and genetics, transcriptomics, proteomics, metabolomics, lipidomics, medicinal chemistry, flow cytometry, advanced imaging techniques, and clinical infectious diseases.

Areas of Interest
  • Antibiotics
  • Beta-lactams
  • Acinetobacter baumannii
  • Aminoglycosides
  • Beta-lactamase inhibitors
  • Eradication of non-replicating bacterial persisters
  • Escherichia coli
  • Klebsiella pneumoniae
  • Mechanism-based mathematical modeling
  • Mechanisms of antibiotic action and synergy
  • Multidrug-resistant bacterial ‘superbugs’ and their resistance mechanisms
  • Omics techniques and single cell analyses
  • Penicillin-binding protein (PBP) occupancy patterns
  • Pharmacodynamics
  • Polymyxins
  • Population pharmacokinetics
  • Pseudomonas aeruginosa
  • Quantitative and Systems Pharmacology modeling
  • Rationally optimizing anti-infective combination dosing strategies
  • Staphylococcus aureus
  • Toxicodynamics
  • Translational drug development


February 2019 – September 2019
New Strain Testing and PK-PD Studies for Therapeutics in Murine Models of Bacterial Thigh Infections
February 2019ACTIVE
Mathematical modeling of antimicrobial resistance
STATE UNIV OF NEW YORK BUFFALO · Principal Investigator
August 2018ACTIVE
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding
NATL INST OF HLTH NIAID · Principal Investigator
November 2017ACTIVE
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii
NATL INST OF HLTH NIAID · Principal Investigator
September 2017ACTIVE
A Preclinical Mouse Model of Acinetobacter buamannii Infection For Antibacterial Development
UNIV OF SOUTHERN CALIFORNIA · Principal Investigator
June 2017ACTIVE
OR-DRPD-ROF2017:Combating resistant Gram-negative bacterial superbugs via omics techniques
UF DSR OPPORTUNITY FUND · Principal Investigator
March 2017 – June 2018
Identification of antiviral therapies for the treatment of Zika virus using existing drugs
FL DEPT OF HLTH · Project Manager
March 2017 – May 2017
Pharmacokinetic optimization of the platelet aggregation inhibitor ticagrelor
March 2017 – May 2017
Supporting the rational development of a generic dutasteride formulation by pharmacokinetic data analyses and simulations
September 2016 – March 2018
Pharmacokinetic Comparison of Locally Acting Orally Inhaled Drug Products
US FOOD AND DRUG ADMN · Principal Investigator
August 2015 – March 2019
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs
STATE UNIV OF NEW YORK BUFFALO · Principal Investigator
December 2014ACTIVE
Comprehensive Evaluation of Formulation Effects on Metered Dose Inhaler Performance
September 2013ACTIVE
Study to Investigate the Sensitivity of Pharmacokinetics in Detecting Differences in Physicochemical Properties of the Active in Suspension Nasal Products for Local Action
US FOOD AND DRUG ADMN · Principal Investigator


Postdoc – Pharmaceutical sciences
University at Buffalo SUNY, Buffalo, NY, USA
Ph.D. – Pharmaceutical sciences / chemistry
University of Würzburg, Germany
M.Sc. – Chemistry (general and computational; minor: Microbiology)
University of Erlangen-Nürnberg, Germany
B.Sc. – Chemistry
University of Erlangen-Nürnberg, Germany

Contact Details

(407) 313-7010
6550 SANGER RD OFC 475